Stephen G. Woodhams

Stephen G. Woodhams

Auto-generated profile, based on publicly available information

Stephen G. Woodhams

Pain Centre Versus Arthritis, University of Nottingham, Medical School, Queen's Medical Centre, Nottingham, United Kingdom

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in Neuropharmacology
Verified
Journal Article
Closed access
SWStephen G. Woodhams
Stephen G. Woodhams
VCVictoria Chapman
Victoria Chapman
DFDavid P. Finn
David P. Finn
AHAndrea G. Hohmann
Andrea G. Hohmann
VNVolker Neugebauer
Volker Neugebauer

8 December 2014 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
BDBarna Dudok
Barna Dudok
LBLászló Barna
László Barna
MLMarco Ledri
Marco Ledri
SSSzilárd I Szabó
Szilárd I Szabó
ESEszter Szabadits
Eszter Szabadits
IKIstván Katona
István Katona
Combining patch-clamp recordings and subsequent STORM imaging of individual cells, the authors show that the axon terminals of perisomatically- and dendritically-projecting GABAergic interneurons show differences in CB1 receptor number, active zone complexity, and receptor:effector ratio. Chronic exposure to THC evoked a dose-dependent and long-lasting downregulation of CB1 at these synapses. A major challenge in neuroscience is to determine the nanoscale position and quantity of signaling molecules in a cell type– and subcellular compartment–specific manner. We developed a new approach to this problem by combining cell-specific physiological and anatomical characterization with super-resolution imaging and studied the molecular and structural parameters shaping the physiological properties of synaptic endocannabinoid signaling in the mouse hippocampus. We found that axon terminals of perisomatically projecting GABAergic interneurons possessed increased CB1 receptor number, active-zone complexity and receptor/effector ratio compared with dendritically projecting interneurons, consistent with higher efficiency of cannabinoid signaling at somatic versus dendritic synapses. Furthermore, chronic Δ9-tetrahydrocannabinol administration, which reduces cannabinoid efficacy on GABA release, evoked marked CB1 downregulation in a dose-dependent manner. Full receptor recovery required several weeks after the cessation of Δ9-tetrahydrocannabinol treatment. These findings indicate that cell type–specific nanoscale analysis of endogenous protein distribution is possible in brain circuits and identify previously unknown molecular properties controlling endocannabinoid signaling and cannabis-induced cognitive dysfunction.

1 January 2015
Verified
Book Chapter
Closed access
PDF file
SWStephen G. Woodhams
Stephen G. Woodhams
DSDevi Rani Sagar
Devi Rani Sagar
JBJames J. Burston
James J. Burston
VCVictoria Chapman
Victoria Chapman

1 January 2015 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
SKS Kelly
S Kelly
RCR J Chapman
R J Chapman
SWS Woodhams
S Woodhams
DSD R Sagar
D R Sagar
JTJ Turner
J Turner
VCVictoria Chapman
Victoria Chapman
Objectives Blockade of transient receptor potential vanilloid 1 (TRPV1) with systemic antagonists attenuates osteoarthritis (OA) pain behaviour in rat models, but on-target-mediated hyperthermia has halted clinical trials. The present study investigated the potential for targeting TRPV1 receptors within the OA joint in order to produce analgesia. Methods The presence of TRPV1 receptors in human synovium was detected using western blotting and immunohistochemistry. In a rat model of OA, joint levels of an endogenous ligand for TRPV1, 12-hydroxy-eicosatetraenoic acid (12-HETE), were quantified using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Effects of peripheral administration of the TRPV1 receptor antagonist JNJ-17203212 on afferent fibre activity, pain behaviour and core body temperature were investigated. Effects of a spinal administration of JNJ-17203212 on dorsal horn neuronal responses were studied. Results We demonstrate increased TRPV1 immunoreactivity in human OA synovium, confirming the diseased joint as a potential therapeutic target for TRPV1-mediated analgesia. In a model of OA pain, we report increased joint levels of 12-HETE, and the sensitisation of joint afferent neurones to mechanical stimulation of the knee. Local administration of JNJ-17203212 reversed this sensitisation of joint afferents and inhibited pain behaviour (weight-bearing asymmetry), to a comparable extent as systemic JNJ-17203212, in this model of OA pain, but did not alter core body temperature. There was no evidence for increased TRPV1 function in the spinal cord in this model of OA pain. Conclusions Our data provide a clinical and mechanistic rationale for the future investigation of the therapeutic benefits of intra-articular administration of TRPV1 antagonists for the treatment of OA pain.

1 January 2011 in Molecular Pain
Verified
Journal Article
Open access
PDF file
DSDevi Rani Sagar
Devi Rani Sagar
JBJames J Burston
James J Burston
GHGareth J Hathway
Gareth J Hathway
SWStephen G Woodhams
Stephen G Woodhams
RPRichard Pearson
Richard Pearson
VCVictoria Chapman
Victoria Chapman
Background: Clinical studies of osteoarthritis (OA) suggest central sensitization may contribute to the chronic pain experienced. This preclinical study used the monosodium iodoacetate (MIA) model of OA joint pain to investigate the potential contribution of spinal sensitization, in particular spinal glial cell activation, to pain behaviour in this model. Experimental OA was induced in the rat by the intra-articular injection of MIA and pain behaviour (change in weight bearing and distal allodynia) was assessed. Spinal cord microglia (Iba1 staining) and astrocyte (GFAP immunofluorescence) activation were measured at 7, 14 and 28 days post MIA-treatment. The effects of two known inhibitors of glial activation, nimesulide and minocycline, on pain behaviour and activation of microglia and astrocytes were assessed. Results: Seven days following intra-articular injection of MIA, microglia in the ipsilateral spinal cord were activated (p < 0. 05, compared to contralateral levels and compared to saline controls). Levels of activated microglia were significantly elevated at day 14 and 21 post MIA-injection. At day 28, microglia activation was significantly correlated with distal allodynia (p < 0.05). Ipsilateral spinal GFAP immunofluorescence was significantly (p < 0.01) increased at day 28, but not at earlier timepoints, in the MIA model, compared to saline controls. Repeated oral dosing (days 14-20) with nimesulide attenuated pain behaviour and the activation of microglia in the ipsilateral spinal cord at day 21. This dosing regimen also significantly attenuated distal allodynia (p < 0.001) and numbers of activated microglia (p < 0.05) and GFAP immunofluorescence (p < 0.001) one week later in MIA-treated rats, compared to vehicle-treated rats. Repeated administration of minocycline also significantly attenuated pain behaviour and reduced the number of activated microglia and decreased GFAP immunofluorescence in ipsilateral spinal cord of MIA treated rats. Conclusions: Here we provide evidence for a contribution of spinal glial cells to pain behaviour, in particular distal allodynia, in this model of osteoarthritic pain. Our data suggest there is a potential role of glial cells in the central sensitization associated with OA, which may provide a novel analgesic target for the treatment of OA pain.

30 November 2010 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
DSDevi Rani Sagar
Devi Rani Sagar
LSLydia E. Staniaszek
Lydia E. Staniaszek
BOBright N. Okine
Bright N. Okine
SWStephen Woodhams
Stephen Woodhams
LNLeonie M. Norris
Leonie M. Norris
VCVictoria Chapman
Victoria Chapman
Objective: To investigate the impact of an experimental model of osteoarthritis (OA) on spinal nociceptive processing and the role of the inhibitory endocannabinoid system in regulating sensory processing at the spinal level.Methods: Experimental OA was induced in rats by intraarticular injection of sodium mono‐iodoacetate (MIA), and the development of pain behavior was assessed. Extracellular single‐unit recordings of wide dynamic range (WDR) neurons in the dorsal horn were obtained in MIA‐treated rats and saline‐treated rats. The levels of endocannabinoids and the protein and messenger RNA levels of the main synthetic enzymes for the endocannabinoids (N‐acyl phosphatidylethanolamine phospholipase D [NAPE‐PLD] and diacylglycerol lipase α [DAGLα]) in the spinal cord were measured.Results: Low‐weight (10 gm) mechanically evoked responses of WDR neurons were significantly (P < 0.05) facilitated 28 days after MIA injection compared with the responses in saline‐treated rats, and spinal cord levels of anandamide and 2‐arachidonoyl glycerol (2‐AG) were increased in MIA‐treated rats. Protein levels of NAPE‐PLD and DAGLα, which synthesize anandamide and 2‐AG, respectively, were elevated in the spinal cords of MIA‐treated rats. The functional role of endocannabinoids in the spinal cords of MIA‐treated rats was increased via activation of cannabinoid 1 (CB1) and CB2 receptors, and blockade of the catabolism of anandamide had significantly greater inhibitory effects in MIA‐treated rats compared with control rats.Conclusion: Our findings provide new evidence for altered spinal nociceptive processing indicative of central sensitization and for adaptive changes in the spinal cord endocannabinoid system in an experimental model of OA. The novel control of spinal cord neuronal responses by spinal cord CB2 receptors suggests that this receptor system may be an important target for the modulation of pain in OA.